Osteoporosis: strategies for prevention and management.
Osteoporosis is a serious public health issue, affecting up to 1 in 2 women and 1 in 5 men over the age of 50 years. The common osteoporotic fractures occur at the spine, wrist and hip. For the patient affected by osteoporosis, these fractures are associated with significant morbidity and, in the case of hip and spine fractures, an excess mortality. The treatment of osteoporotic fractures is also associated with a significant healthcare cost for society. Currently, measurement of bone mineral density using dual energy X-ray absorptiometry is the gold standard for the diagnosis of osteoporosis. In the future, however, assessment of fracture risk will be based on algorithms incorporating clinical risk factors and bone density measurements, where appropriate. The goal of treatment is to reduce the risk of future fracture. Patients at high risk for fracture should be assessed and screened to exclude secondary causes for osteoporosis. Bisphosphonates (alendronate, etidronate, ibandronate, risedronate) are the first-line therapy for the majority of patients and these treatments can be given either orally or intravenously. Alternative treatment options include strontium ranelate and raloxifene. Anabolic therapy with parathyroid hormone can be considered for patients with severe disease. These patients will often require referral for specialist assessment and monitoring. All patients at risk of developing osteoporosis should be given lifestyle advice regarding dietary intake of calcium and vitamin D and regular weight-bearing exercise.
Keen
Richard
R
Institute of Orthopaedics and Musculoskeletal Sciences, The Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex HA7 4LP, UK. richard.keen@ucl.ac.uk
D002116:Calcitonin / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D019468:Disease Management; D005260:Female; D050723:Fractures, Bone / Q000150:complications / Q000453:epidemiology; D020249:Hormone Replacement Therapy; D006801:Humans; D008019:Life Style; D009942:Organometallic Compounds / Q000627:therapeutic use; D010024:Osteoporosis / Q000150:complications / Q000517:prevention & control* / Q000628:therapy; D010281:Parathyroid Hormone / Q000627:therapeutic use; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use
D004164:Diphosphonates; D009942:Organometallic Compounds; D010281:Parathyroid Hormone; D020845:Selective Estrogen Receptor Modulators; D013876:Thiophenes; C081587:strontium ranelate; D002116:Calcitonin